All
Mohs surgery, topical chemotherapy are gold standards
February 1st 2008Mohs surgery and topical chemotherapy are among the most effective treatments for certain types of skin cancer, according to David J. Goldberg, M.D. In the very near future, however, photodynamic therapy - now commonly used with good results in Europe - may well become the gold-standard treatment for skin cancers in the United States.
Psoriasis considered risk factor for cardiovascular disease
February 1st 2008Epidemiological data on the prevalence and degree of cardiovascular morbidity and mortality in patients with psoriasis are contradictory. A team of German researchers recently found that the patients with psoriasis have an increased coronary artery calcification, which precedes myocardial infarction. Thus, psoriasis can be considered as a risk factor for cardiovascular disease.
Combination product offers stability, flexibility in acne patient care
February 1st 2008Results from a series of in vitro studies show a new combination clindamycin/tretinoin product (Zianis, Medicis) may potentially be applied sequentially with benzoyl peroxide without concern about loss of activity from tretinoin degradation.
A well-running team, process are paramount in conducting a research study
February 1st 2008Conducting a pilot study is key to launching a successful larger research study. In a pilot study, researchers can identify shortcomings like poor adherence and how to address those shortcomings. A timetable for a research study should be established, taking into account the experience and competence of the principal investigator and research team. Data should be reviewed in the initial phase of a research study, when missing information can be more easily retrieved, to minimize the amount of data missing in a study.
HUMIRA receives FDA approval for the treatment of plaque psoriasis
January 21st 2008Abbott Park, Ill. ? Abbot announces it has received U.S. Food and Drug Administration (FDA) approval for HUMIRA (adalimumab) as a treatment for adult patients with moderate to severe chronic plaque psoriasis, PRNewswire reports.
Research uncovers potential of sulforaphane as therapy for epidermolysis bullosa simplex
January 3rd 2008Washington - Sulforaphane, a natural compound found in broccoli and other cruciferous vegetables, may be effective in helping treat epidermolysis bullosa simplex, according to research presented during the annual meeting of the American Society for Cell Biology, held here recently and reported on by Reuters Health.
Study warns against use of quinapril to treat digital ulcers in cutaneous sclerosis patients
January 3rd 2008Bangor, Wales - British researchers report that quinapril, a long-acting angiotensin-converting enzyme (ACE) inhibitor, does not appear to prevent upper-limb digital ulcers or other vascular manifestations in patients with limited cutaneous systemic sclerosis (lcSSc), reports Reuters Health.
Testing set for ArteFill’s use in treating acne scars
January 3rd 2008St. Petersburg, Fla. - Testing is set to begin on ArteFill (polymethylmethacrylate, Artes Medical) for the treatment of acne scars and other depressed atrophic scars, reports MedicalNewsToday.com. St. Petersburg-based dermatologist James Spencer, M.D., will head the study.
Per agreement with Galderma, Anika reaquires rights to Elevess dermal filler products
January 3rd 2008Bedford, Mass. - Anika Therapeutics, based here, announced that Anika and Galderma have finalized their agreement to terminate all license, development and supply arrangements involving the Elevess family of filler products, reports MedicalNewsToday.com.
Despite contrary report, UK health agency says bath products help in managing eczema
January 3rd 2008London - In the wake of a recent report stating that bath products do little to combat eczema in children, Great Britain’s National Health Service is endorsing such products as being effective in helping to manage the disease, reports BBCNews.
Bristol-Myers Squibb, Medarex set to seek FDA approval for their melanoma drug
January 3rd 2008New York - Bristol-Myers Squibb Co., based here, and Medarex Inc., Princeton, N.J., are reporting mixed results from three studies of the experimental drug ipilimumab for treating advanced melanoma, according to news source Reuters.